Because ErbB2 overexpression renders breast tumor cells anoikis-resistant, mechanisms of this resistance are potential novel targets for treatment of ErbB2-positive breast cancers, and mediators of this resistance are potential biomarkers of breast tumor sensitivity to ErbB2 antagonists. This evidence concerns the gene ERBB2 and breast carcinoma.